COSCIENS Biopharma Inc. (TSX:CSCI)
Canada
· Delayed Price · Currency is CAD 2.670
+0.070 (2.69%)
Apr 28, 2026, 1:39 PM EST
COSCIENS Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 7.5 | 9.59 | 7.14 | 14.57 | 5.26 | Upgrade
|
| Revenue Growth (YoY) | -21.79% | 34.22% | -50.98% | 177.03% | 44.03% | Upgrade
|
| Cost of Revenue | 4.93 | 4.86 | 4.21 | 6.02 | 0.09 | Upgrade
|
| Gross Profit | 2.57 | 4.73 | 2.94 | 8.56 | 5.17 | Upgrade
|
| Selling, General & Admin | 10.06 | 6.37 | 5.53 | 2.87 | 7.27 | Upgrade
|
| Research & Development | 2.95 | 8.3 | 2.04 | 1.37 | 6.57 | Upgrade
|
| Operating Expenses | 13.01 | 14.67 | 7.57 | 4.24 | 13.84 | Upgrade
|
| Operating Income | -10.44 | -9.94 | -4.63 | 4.32 | -8.67 | Upgrade
|
| Interest Expense | -0.17 | -0.13 | -0.14 | -0.14 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.28 | 0.44 | 0.06 | 0.15 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.2 | 0.05 | -0.02 | 0.21 | 0.22 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.41 | 2.7 | 0.36 | -0.01 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -10.11 | -6.89 | -4.37 | 4.53 | -8.48 | Upgrade
|
| Merger & Restructuring Charges | - | -4.08 | - | - | - | Upgrade
|
| Asset Writedown | -0.24 | -4.26 | - | - | - | Upgrade
|
| Pretax Income | -10.35 | -15.23 | -4.37 | 4.53 | -8.48 | Upgrade
|
| Income Tax Expense | 0.01 | 0.08 | -0.89 | 1.08 | -0.11 | Upgrade
|
| Earnings From Continuing Operations | -10.36 | -15.31 | -3.49 | 3.45 | -8.37 | Upgrade
|
| Net Income | -10.36 | -15.31 | -3.49 | 3.45 | -8.37 | Upgrade
|
| Net Income to Common | -10.36 | -15.31 | -3.49 | 3.45 | -8.37 | Upgrade
|
| Shares Outstanding (Basic) | 3 | 3 | 2 | 2 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 3 | 2 | 2 | 1 | Upgrade
|
| Shares Change (YoY) | 22.62% | 39.74% | -0.39% | 61.37% | 179.74% | Upgrade
|
| EPS (Basic) | -3.27 | -5.93 | -1.89 | 1.87 | -7.28 | Upgrade
|
| EPS (Diluted) | -3.27 | -5.93 | -1.89 | 1.86 | -7.28 | Upgrade
|
| Free Cash Flow | -9.18 | -15.73 | -3.3 | 4.93 | -8.61 | Upgrade
|
| Free Cash Flow Per Share | -2.90 | -6.09 | -1.79 | 2.66 | -7.49 | Upgrade
|
| Gross Margin | 34.29% | 49.33% | 41.13% | 58.71% | 98.29% | Upgrade
|
| Operating Margin | -139.25% | -103.70% | -64.81% | 29.65% | -164.85% | Upgrade
|
| Profit Margin | -138.14% | -159.69% | -48.79% | 23.66% | -159.09% | Upgrade
|
| Free Cash Flow Margin | -122.42% | -164.07% | -46.26% | 33.80% | -163.71% | Upgrade
|
| EBITDA | -9.52 | -8.68 | -3.19 | 5.79 | -8.53 | Upgrade
|
| EBITDA Margin | -126.90% | -90.52% | -44.60% | 39.72% | -162.09% | Upgrade
|
| D&A For EBITDA | 0.93 | 1.26 | 1.44 | 1.47 | 0.15 | Upgrade
|
| EBIT | -10.44 | -9.94 | -4.63 | 4.32 | -8.67 | Upgrade
|
| EBIT Margin | -139.25% | -103.70% | -64.81% | 29.65% | -164.85% | Upgrade
|
| Effective Tax Rate | - | - | - | 23.85% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.